Developing an inhibitory treatment against CCL2 elevation in patients with IIH could be advantageous in reducing this resistance of CSF drainage, possibly around the arachnoid granulations, and therefore lowering ICP. This evidence concerns the gene CCL2 and pseudotumor cerebri.